The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics and treatment outcomes of hepatosplenic T-cell lymphoma: Mayo Clinic experience.
 
Syeda Mina
No Relationships to Disclose
 
Raphael Mwangi
No Relationships to Disclose
 
Ayo Falade
No Relationships to Disclose
 
Paul Hampel
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - AstraZeneca (Inst); BeiGene (Inst)
 
Jonas Paludo
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst)
Research Funding - Biofourmis (Inst); Karyopharm Therapeutics (Inst)
 
Gita Thanarajasingam
Consulting or Advisory Role - Novartis (Inst)
 
Carrie Thompson
No Relationships to Disclose
 
Talal Hilal
Research Funding - BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst)
 
Adrienne Nedved
Honoraria - UpToDate
Other Relationship - Axis Medical Education
 
Urshila Durani
No Relationships to Disclose
 
Robin Klebig
No Relationships to Disclose
 
Muhamad Alhaj Moustafa
Consulting or Advisory Role - Abbvie; Cancer Network
 
Grzegorz Nowakowski
Consulting or Advisory Role - Abbvie; Bantam Pharmaceutical; Bristol-Myers Squibb/Celgene; Celgene (Inst); Debiopharm Group; Genentech (Inst); Genmab; Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Roche Pharma AG (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
James Cerhan
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Protagonist Therapeutics
Research Funding - Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genmab (Inst)
(OPTIONAL) Uncompensated Relationships - Regeneron (Inst)
 
Thomas Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - BeiGene; Incyte; Loxo/Lilly; MorphoSys; Seagen; Tessa Therapeutics
 
Stephen Ansell
Honoraria - Answers in CME; Medscape; Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Step Pharma (Inst); Takeda (Inst)
 
Thomas Witzig
Consulting or Advisory Role - Tornado Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Nabila Bennani
Consulting or Advisory Role - Acrotech Biopharma (Inst); Affimed Therapeutics (Inst); Astellas Pharma (Inst)
Research Funding - Vyriad (Inst)
 
Jithma Abeykoon
No Relationships to Disclose